VRXA VRXA
Company Profile ↓Company Overview
VRXA (VRXA) is a publicly traded company listed on with a market capitalization of $248.88M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -83.08% |
| 6 Months: | -83.57% |
| 3 Months: | -83.40% |
| 1 Month: | -5.38% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 92.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 23.43K |
| Cost of Revenue | - | 0 | 7.96K |
| Gross Profit | - | 0 | 15.46K |
| Operating Expenses | 16.66M | 28.92M | 66.23M |
| Operating Income | -16.66M | -28.92M | -66.22M |
| EBITDA | -15.81M | -26.88M | -64.91M |
| Interest Expense | 1.09K | 291 | 3.55K |
| Pretax Income | -17.66M | -28.75M | -67.01M |
| Tax Provision | -1.11M | -620.77K | -392.60K |
| Net Income | -16.54M | -28.13M | -66.61M |
| Diluted EPS | -0.12 | -0.20 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 91.94M | 84.77M | 80.82M |
| Current Assets | 11.88M | 5.61M | 2.88M |
| Cash & Equivalents | 11.35M | 5.36M | 1.61M |
| Inventory | - | - | - |
| Receivables | 257.76K | 174.87K | 1.17M |
| Total Liabilities | 36.81M | 53.71M | 96.59M |
| Current Liabilities | 1.61M | 2.55M | 6.61M |
| Long Term Debt | - | - | - |
| Total Debt | 0 | 864.49K | 2.14M |
| Total Equity | 55.13M | 31.05M | -15.77M |
| Shares Outstanding | 141.41M | 141.41M | 141.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -7.27M | -7.72M | -9.90M |
| Investing Cash Flow | -1.02M | -120.88K | -437.18K |
| Financing Cash Flow | 12.54M | 1.85M | 6.59M |
| Capital Expenditure | -232.31K | -120.88K | -437.18K |
| Free Cash Flow | -7.50M | -7.84M | -10.34M |
| Net Change in Cash | 4.25M | -5.99M | -3.75M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | 66.0% |
| Operating Margin % | - | - | -282,662.7% |
| Net Margin % | - | - | -284,359.2% |
| ROE % | -30.0% | -90.6% | 422.5% |
| ROCE % | -18.4% | -35.2% | -89.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRXA
Veraxa Biotech (VRXA) Insider Trading Activity 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5vbkZfdWpDbWRxMjN2UjYtOFRXU1Rac0pyN0trTFhzS2V3YWpKUDBpaHp4Z05NYjF1WDBKdk1qQi1Nalc5OTg4Ti1icV9xZk5qOXEyMnpGV19vdGdvTlFnQTZ6Mkc1YnpSeTlfVDJB?oc=5" target="_blank">Veraxa Biotech (VRX…
$VRXA stock is up 15% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOTm5zUXZYQkxRemNjTl9maHNVaGNJejdIbFNjS195RWc1YlhlTjEwaGZBUUx0dUd1d2Jnay1OdHdFQmZ1Q3NvVnJubWhTNGdRcHI2c2gwOV9PbmRiNmkzQ0ttVF9pZERzNUFoTDAtZDB6YXRjbEZzNTVMYnltLV9jUkJfTFp6SUliMlg1dU…
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer - Benzinga
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNdVRNTzBYd0FsZGlTemtVSjRLQXN5bkxvX2IzRjI1U204SGtMZmRpUVgxeUdWd1Rkal9FVmVlZVl2dUdpNjlKb1hGdXBMa2pvR2UtVmdxa2ctYWNmdTJkZGpndjg0UE42NlE0SGdETGFKV3EwRDBvd0pDcm9sTF9jMXpuNlZzVnI4bVdSSG…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1xRDRvWXZyVnRSeUtMa3RxZjZ0d1NOSEo3OURBemd0Q0FQVDN3N0pVRi1JSHlieDYxSlVZdjRfdTd6VEFPeXo4RXdPWm5SZ1J6?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Finance veteran behind CHF 30B portfolios joins Veraxa Biotech (VRXA) as CFO - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNemdMX2ZuTXZmaDY5cGh3QkxVdWEzdkVEekJudFZrSHZGaHdvQ1VYblRka2Yxc25qOWxoeGM1RzYzWUdELW1QSGpNSjBvcEMxUC13dEhvQzNaNlhyVUVQTTNvRnN6MF9fX0I4LUtIT0VIdW8wSXphVENzblRKOW90RV9pYUVKWXRFbVFNdW…
Insider Buys Additional CHF75k In Veraxa Biotech Stock - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNeG5TMFhvYU12Q1pjWDRHUGJkOHZsblo5OFY4b1EteEl5SFdjcnlWcVB1Vko5QmhibVlWbmxoOXBYaE4xcS1PVGdYTW1mWERiOE9HcnJlQ0hSdGFoNTFtbGJ5dHhFb3BWRDVMMkJGQnQxclhMMUNlSjlUNVN4MDVwVHM5ZWJIREVYWTJIZm…
VRXA — Frequently Asked Questions
What is the current share price of VRXA?
As of 2026-09-19 21:16 PDT, VRXA trades at $1.76 on NASDAQ/NYSE. Its 52-week range is $1.35 to $24.79.
What is the market capitalisation of VRXA?
VRXA has a market capitalisation of $248.88M on NASDAQ/NYSE.
What is the P/E ratio of VRXA?
VRXA trades at a trailing price-to-earnings (P/E) ratio of -8.85. Its price-to-book (P/B) ratio is -15.78.
Is VRXA a good stock to buy?
This page provides a data-driven analysis of VRXA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.